Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet
Acumen Pharmaceuticals is a clinical-stage Alzheimer's biotech built around sabirnetug. I believe 2026 will be mostly about its upcoming Phase 2 readout. The main appeal still lies with sabirnetug, which could offer meaningful upside if Phase 2 data supports a viable path into Phase 3. As such, ALTITUDE-AD is the main swing factor, especially if iADRS slowing lands near management's target.
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 67,375 | $149,913.6 | $154,288.75 | $4,375.15 | 2.92% |
| CCP Christopher C. Powers Farther Finance Advisors, LLC | 200 | $232 | $458 | $226 | 97.41% |
| CAL Clune & Associates Ltd. Clune & Associates Ltd. | 16,500 | $28,380 | $37,785 | $9,405 | 33.14% |
Acumen Pharmaceuticals, Inc. (ABOS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Acumen Pharmaceuticals, Inc. ever had a stock split?
Acumen Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daniel J. O'Connell CEO | NASDAQ (NGS) Exchange | 00509G209 CUSIP |
| US Country | 61 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for Alzheimer's disease. With a focus on innovation and a pioneering approach to treatment, this company is at the forefront of advancing research and therapy options for one of the most challenging neurodegenerative diseases faced globally. Founded in 1996 and based in Charlottesville, Virginia, Acumen Pharmaceuticals has established itself as a leader in the field, aiming to significantly impact the lives of patients suffering from Alzheimer's disease through groundbreaking treatment solutions.
Products and Services
- Sabirnetug (ACU193)
- Manufacturing and Commercialization Agreement with Lonza Sales AG
- Collaboration and License Agreement with Halozyme, Inc.
A flagship product, sabirnetug (ACU193), represents the core of Acumen Pharmaceuticals’ targeted immunotherapy offerings. It is a recombinant humanized immunoglobulin gamma 2 designed specifically to target soluble amyloid-beta oligomers. Soluble amyloid-beta oligomers are believed to play a critical role in the development and progression of Alzheimer's disease, making ACU193 a significant advancement in targeted therapy. Having completed Phase I clinical trials, sabirnetug is at the forefront of Acumen’s mission to fight Alzheimer's disease.
Acumen Pharmaceuticals has entered into a license agreement with Lonza Sales AG, which encompasses the manufacture and commercialization of sabirnetug. This partnership highlights the company's strategic steps toward ensuring the availability and scalability of this promising therapeutic candidate, emphasizing its commitment to advancing care for Alzheimer's disease patients.
The collaboration with Halozyme, Inc. focuses on the development of a subcutaneous formulation of sabirnetug. This innovative approach aims to improve the delivery and efficacy of the treatment, making it more accessible and potentially more effective for patients. The partnership with Halozyme, Inc. underlines Acumen’s dedication to enhancing Alzheimer's disease treatments through scientific and strategic collaborations.
